BIT Capital GmbH Purchases 50,626 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

BIT Capital GmbH boosted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 41.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 171,714 shares of the company's stock after purchasing an additional 50,626 shares during the quarter. BIT Capital GmbH owned about 0.17% of Day One Biopharmaceuticals worth $2,176,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in DAWN. Algert Global LLC boosted its stake in Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company's stock valued at $996,000 after buying an additional 50,990 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at approximately $866,000. Charles Schwab Investment Management Inc. grew its stake in shares of Day One Biopharmaceuticals by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company's stock worth $7,069,000 after buying an additional 64,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Day One Biopharmaceuticals by 90.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company's stock valued at $1,535,000 after acquiring an additional 57,601 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Day One Biopharmaceuticals by 10.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company's stock worth $19,961,000 after purchasing an additional 136,458 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company's stock.

Remove Ads

Day One Biopharmaceuticals Trading Down 5.0 %

Day One Biopharmaceuticals stock traded down $0.40 during trading on Monday, hitting $7.67. 307,345 shares of the company were exchanged, compared to its average volume of 1,165,702. The business's 50 day moving average is $10.60 and its 200 day moving average is $12.59. Day One Biopharmaceuticals, Inc. has a 52 week low of $7.54 and a 52 week high of $18.07. The company has a market capitalization of $777.09 million, a P/E ratio of -7.44 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analysts' expectations of $27.11 million. Equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the sale, the chief financial officer now directly owns 252,638 shares in the company, valued at $3,021,550.48. This represents a 1.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DAWN shares. Wedbush reiterated an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. The Goldman Sachs Group dropped their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research report on Tuesday, March 25th. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, HC Wainwright decreased their target price on Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $32.29.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.